Literature DB >> 14675663

Uterine papillary serous carcinoma (UPSC): a single institution review of 129 cases.

Brian M Slomovitz1, Thomas W Burke, Patricia J Eifel, Lois M Ramondetta, Elvio G Silva, Anuja Jhingran, Jonathan C Oh, E Neely Atkinson, Russell R Broaddus, David M Gershenson, Karen H Lu.   

Abstract

OBJECTIVE: The aim of this study was to identify clinical and pathologic characteristics of patients with uterine papillary serous carcinoma (UPSC) who were all surgically managed at a single institution. The identified characteristics were then correlated with overall survival (OS).
METHODS: One hundred twenty-nine patients with FIGO stage I-IV UPSC who were surgically staged at the University of Texas M. D. Anderson Cancer Center between 1989 and 2002 were identified. For each patient, medical records and pathology reports were reviewed. The Kaplan-Meier method was used to generate OS data. Factors predictive of outcome were compared using the log-rank test and Cox regression analysis.
RESULTS: There were 52 patients with stage I disease, 5 with stage II, 41 with stage III, and 31 with stage IV. The median age at the time of diagnosis was 68 years (range, 44-93 years). A personal history of breast cancer was reported by 12.4% of the patients, and a family history of breast cancer was reported by 16%. The 5-year OS among all patients was 45.9%. Among the stage I patients (IA, n = 19; IB, n = 26; and IC, n = 7), the 5-year OS was 62.9% (IA, 81.5%; IB, 58.6%; and IC, 34.3%). The 5-year OS for patients with stage III and IV disease was 37.3 and 19.9%, respectively. Pathologic features predictive of OS included lymph node status (P </= 0.01), lymph vascular invasion (P </= 0.05), and depth of uterine invasion (P </= 0.05). Among patients with no uterine invasion (n = 32), surgical staging revealed that 37% had stage III or IV disease. Among stage III patients, those who received chemotherapy had a longer OS than those who did not receive chemotherapy (P = 0.03).
CONCLUSION: In this population of nonselected patients with UPSC, approximately 20% had a personal or family history of breast cancer. Stage, lymph node status, lymph vascular invasion, and depth of myometrial invasion were all risk factors for a worse prognosis. Traditional risk factors, however, did not predict the presence or the absence of metastasis. Among patients with noninvasive uterine disease, there was a high proportion with abdominal metastasis. Therefore, complete surgical staging of these patients is vital in determining their prognosis.

Entities:  

Mesh:

Year:  2003        PMID: 14675663     DOI: 10.1016/j.ygyno.2003.08.018

Source DB:  PubMed          Journal:  Gynecol Oncol        ISSN: 0090-8258            Impact factor:   5.482


  61 in total

1.  Endometrial serous carcinoma (uterine papillary serous carcinoma): precancerous lesions and the theoretical promise of a preventive approach.

Authors:  Oluwole Fadare; Wenxin Zheng
Journal:  Am J Cancer Res       Date:  2012-04-21       Impact factor: 6.166

2.  A clinical and pathologic comparison between stage-matched endometrial intraepithelial carcinoma and uterine serous carcinoma: is there a difference?

Authors:  June Y Hou; Thomas C McAndrew; Gary L Goldberg; Kathleen Whitney; Shohreh Shahabi
Journal:  Reprod Sci       Date:  2013-09-10       Impact factor: 3.060

3.  Solitomab, an EpCAM/CD3 bispecific antibody construct (BiTE), is highly active against primary uterine serous papillary carcinoma cell lines in vitro.

Authors:  Stefania Bellone; Jonathan Black; Diana P English; Carlton L Schwab; Salvatore Lopez; Emiliano Cocco; Elena Bonazzoli; Federica Predolini; Francesca Ferrari; Elena Ratner; Dan-Arin Silasi; Masoud Azodi; Peter E Schwartz; Alessandro D Santin
Journal:  Am J Obstet Gynecol       Date:  2015-08-10       Impact factor: 8.661

4.  A prospective phase II study of chemoradiation followed by adjuvant chemotherapy for FIGO stage I-IIIA (1988) uterine papillary serous carcinoma of the endometrium.

Authors:  Anuja Jhingran; Lois M Ramondetta; Diane C Bodurka; Brian M Slomovitz; Jubilee Brown; Lawrence B Levy; Michael E Garcia; Patricia J Eifel; Karen H Lu; Thomas W Burke
Journal:  Gynecol Oncol       Date:  2013-02-04       Impact factor: 5.482

Review 5.  [Metastatic mechanisms of uterine malignancies and therapeutic consequences].

Authors:  S F Lax; K F Tamussino; P F Lang
Journal:  Pathologe       Date:  2016-11       Impact factor: 1.011

6.  Grade 1 Endometrioid Carcinoma With an Area of Serous Carcinoma Less than 5% Is More Aggressive than Stage IA Pure-type Grade 1 Endometrioid Carcinoma.

Authors:  Morikazu Miyamoto; Hitoshi Tsuda; Atsushi Sugiura; Tsunekazu Kita; Yoshitaka Kataoka; Kenji Ishii; Kazuya Kudo; Hiroko Matsuura; Hiroki Ishibashi; Hideki Iwahashi; Taira Hada; Rie Suzuki; Masashi Takano
Journal:  In Vivo       Date:  2021 Mar-Apr       Impact factor: 2.155

Review 7.  Controversies in the Management of Early-stage Serous Endometrial Cancer.

Authors:  Alyssa Larish; Andrea Mariani; Carrie Langstraat
Journal:  In Vivo       Date:  2021 Mar-Apr       Impact factor: 2.155

8.  Insights into endometrial serous carcinogenesis and progression.

Authors:  Oluwole Fadare; Wenxin Zheng
Journal:  Int J Clin Exp Pathol       Date:  2009-01-10

9.  Tubulin-β-III overexpression by uterine serous carcinomas is a marker for poor overall survival after platinum/taxane chemotherapy and sensitivity to epothilones.

Authors:  Dana M Roque; Stefania Bellone; Diana P English; Natalia Buza; Emiliano Cocco; Sara Gasparrini; Ileana Bortolomai; Elena Ratner; Dan-Arin Silasi; Masoud Azodi; Thomas J Rutherford; Peter E Schwartz; Alessandro D Santin
Journal:  Cancer       Date:  2013-04-12       Impact factor: 6.860

Review 10.  HER2 expression beyond breast cancer: therapeutic implications for gynecologic malignancies.

Authors:  Diana P English; Dana M Roque; Alessandro D Santin
Journal:  Mol Diagn Ther       Date:  2013-04       Impact factor: 4.074

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.